Recombinant Yersinia pseudotuberculosis serotype IB NAD-dependent malic enzyme (maeA), partial

What is Yersinia pseudotuberculosis NAD-dependent malic enzyme (maeA) and what is its biochemical function?

Yersinia pseudotuberculosis NAD-dependent malic enzyme (maeA) is an oxidative decarboxylase that catalyzes the conversion of L-malate to pyruvate and CO₂ with the concomitant reduction of NAD⁺ to NADH. This enzyme plays a critical role in the carbon metabolism of Y. pseudotuberculosis, contributing to energy production and biosynthetic processes. Unlike its human counterpart which can utilize both NAD⁺ and NADP⁺ as cofactors (NAD(P)⁺-dependent malic enzyme), the bacterial maeA typically demonstrates a strong preference for NAD⁺ . The enzyme belongs to the malic enzyme family that is widely distributed across prokaryotic and eukaryotic organisms, with conserved catalytic domains but variations in regulatory mechanisms. In the context of Y. pseudotuberculosis metabolism, maeA contributes to the generation of pyruvate, which serves as a key metabolic intermediate for various biosynthetic pathways and energy production via the TCA cycle.

What are the optimal methods for expressing and purifying recombinant Y. pseudotuberculosis maeA?

Expression and purification of recombinant Y. pseudotuberculosis maeA typically follows standard molecular biology approaches with specific optimizations:

Expression System Selection:

• E. coli BL21(DE3) is commonly employed due to its low protease activity and compatibility with T7 promoter-based expression systems

• Expression vectors incorporating a His-Tag (commonly hexahistidine) fusion facilitate subsequent purification

Optimized Expression Protocol:

• Transform expression vector into host cells and culture in appropriate media (typically LB with selective antibiotics)

• Induce protein expression at OD₆₀₀ of 0.6-0.8 with IPTG (0.1-1.0 mM)

• Continue growth at lower temperature (16-25°C) for 12-18 hours to minimize inclusion body formation

• Harvest cells by centrifugation and lyse using mechanical disruption or detergent-based methods

Purification Strategy:

• Ni-NTA affinity chromatography for initial capture of His-tagged protein

• Size exclusion chromatography for further purification and buffer exchange

• Optional ion exchange chromatography step for removal of remaining contaminants

Yield Optimization Using Design of Experiments (DoE):
Applying fractional factorial designs as described in recent literature can significantly improve expression yields by simultaneously optimizing multiple variables :

This approach has been reported to increase yield by up to 60% compared to traditional one-factor-at-a-time optimization strategies .

How is Y. pseudotuberculosis maeA regulated, and how does this compare to human mitochondrial malic enzyme?

The allosteric regulation of Y. pseudotuberculosis maeA shares some similarities with human mitochondrial NAD(P)⁺-dependent malic enzyme (m-NAD(P)-ME) but exhibits distinct regulatory mechanisms:

Allosteric Regulation:

• Fumarate activation: While human m-NAD(P)-ME is allosterically activated by fumarate (a four-carbon trans dicarboxylic acid), bacterial malic enzymes often show different responses to this metabolite .

• Structural basis: In human m-NAD(P)-ME, the trans conformation around the carbon-carbon double bond in fumarate is crucial for allosteric activation, as demonstrated in studies with fumarate analogs .

Inhibitory Mechanisms:

• Several fumarate analogs have been identified as inhibitors of human m-NAD(P)-ME, including oxaloacetate, diethyl oxalacetate, and dimethyl fumarate, with IC₅₀ values in the millimolar range .

• The bacterial maeA may respond differently to these compounds, offering potential selective targeting opportunities.

Structural Comparisons:
The human m-NAD(P)-ME structure consists of four domains (A-D), with domains B and C forming the active site. Key residues in human ME that interact with fumarate include Arg67, Arg91, Lys57, Glu59, Lys73, and Asp102 . Comparative analysis with bacterial maeA sequences can identify conserved or divergent regulatory sites.

Understanding these regulatory differences could potentially be exploited for developing selective inhibitors for bacterial malic enzymes as antibiotic targets.

What are the recommended methodologies for studying Y. pseudotuberculosis maeA enzyme kinetics?

Several complementary approaches can be employed to characterize the kinetic properties of Y. pseudotuberculosis maeA:

Spectrophotometric Assays:
The primary method utilizes the change in absorbance at 340 nm due to NAD⁺ reduction to NADH:

• Reaction mixture typically contains: L-malate (0.1-10 mM), NAD⁺ (0.05-2 mM), metal cofactor (usually Mn²⁺ or Mg²⁺, 1-5 mM), and buffer (typically HEPES or Tris, pH 7.2-7.8)

• Monitor rate of NADH formation at 340 nm (ε = 6,220 M⁻¹cm⁻¹)

• Calculate enzyme activity in μmol NADH formed/min/mg protein

Steady-State Kinetic Analysis:

• Determine initial reaction rates at varying substrate concentrations

• Plot data using appropriate models (Michaelis-Menten, Lineweaver-Burk, Eadie-Hofstee)

• Calculate kinetic parameters (Km, Vmax, kcat, kcat/Km)

Transient Kinetics:
For more detailed mechanistic insights, employ stopped-flow spectroscopy to investigate:

• Pre-steady-state kinetics

• Order of substrate binding

• Rate-limiting steps in the reaction

Inhibition Studies:
To investigate potential inhibitors:

• Determine type of inhibition (competitive, non-competitive, uncompetitive, mixed)

• Calculate inhibition constants (Ki)

• Analyze structure-activity relationships

Thermal Shift Assays:
To verify binding of substrates, cofactors, or inhibitors:

• Use fluorescent dyes (e.g., SYPRO Orange) that bind to hydrophobic regions exposed upon protein unfolding

• Monitor thermal denaturation curves in presence/absence of ligands

• Shifts in melting temperature (Tm) indicate ligand binding

These methodological approaches provide complementary data for comprehensive characterization of the enzyme's kinetic properties, regulatory mechanisms, and inhibitor interactions.

How can factorial experimental design be applied to optimize recombinant Y. pseudotuberculosis maeA expression and activity studies?

Fractional factorial designs provide an efficient approach to optimize multiple parameters simultaneously in maeA research:

Principle and Rationale:
The sparsity of effects principle underlies fractional factorial designs, asserting that most responses are affected by a small number of main effects and lower-order interactions, while higher-order interactions are relatively unimportant . This approach is particularly valuable for initial screening experiments involving multiple factors.

Implementation for maeA Expression Optimization:
A half-fraction design with five factors at two levels (2^5-1) requires only 16 runs instead of 32 for a full factorial design:

Analysis and Optimization:

• Analysis of main effects using statistical software (e.g., R, JMP, Design-Expert)

• Pareto charts to visualize the significance of different factors

• Response surface methodology (RSM) for subsequent fine-tuning of the most significant factors

Example experimental design matrix:

This approach can identify optimal conditions while using fewer experiments than traditional methods, reducing time and resource requirements. The same methodology can be applied to optimize enzyme assay conditions, purification protocols, or screening for inhibitors .

What is the role of Y. pseudotuberculosis in pathogenicity, and how might maeA contribute to its virulence?

Y. pseudotuberculosis is a significant pathogen with well-characterized virulence mechanisms, though the specific contribution of maeA to pathogenicity remains an area for investigation:

Y. pseudotuberculosis Pathogenicity:
Y. pseudotuberculosis causes zoonotic infections that typically manifest as gastroenteritis with symptoms resembling appendicitis. This bacterium is a close relative of Yersinia pestis (the causative agent of plague) but produces a milder disease :

• Transmission: Occurs through the food-borne route or contact with infected animals .

• Reservoir: The bacterium typically resides in warm-blooded animals including mammals (dogs, cats, cattle, rodents) and birds (turkeys, ducks) .

• Disease progression: After ingestion, Y. pseudotuberculosis colonizes the gastrointestinal tract, particularly Peyer's patches in the distal small intestine, and can disseminate to the liver and spleen directly or via mesenteric lymph nodes .

• Clinical manifestations: Include abdominal pain, fever, and occasionally skin rash (erythema nodosum), with notably less diarrhea than Y. enterocolitica infections .

Potential Role of maeA in Virulence:
While the direct contribution of maeA to virulence has not been fully elucidated, several potential mechanisms can be hypothesized based on our understanding of bacterial metabolism and host-pathogen interactions:

• Metabolic adaptation: maeA likely contributes to the bacterium's ability to adapt to different metabolic environments encountered during infection, facilitating survival within host tissues.

• Energy generation: The conversion of malate to pyruvate with concomitant NAD⁺ reduction provides energy and biosynthetic precursors that may be crucial during infection.

• pH homeostasis: The decarboxylation reaction catalyzed by maeA could contribute to pH regulation, potentially helping the bacterium survive in acidic environments encountered during infection.

Research Directions:
To investigate maeA's role in virulence, researchers could pursue:

• Construction of maeA-deficient Y. pseudotuberculosis strains and comparative virulence studies

• Transcriptomic/proteomic analysis of maeA expression during infection

• Metabolomic profiling to understand alterations in central metabolism during infection

Understanding the potential contribution of maeA to Y. pseudotuberculosis pathogenicity could inform new therapeutic strategies targeting bacterial metabolism.

How can recombinant Y. pseudotuberculosis strains be used in vaccine development against Yersinia infections?

Recombinant attenuated Y. pseudotuberculosis strains have shown significant promise as vaccine delivery platforms:

Current Approaches:
Research has demonstrated that engineered Y. pseudotuberculosis strains can be used to develop effective vaccines against multiple Yersinia species infections :

• Attenuation strategies: Deletion of virulence factors such as YopK (involved in type III secretion system regulation), YopJ (which inhibits inflammatory responses), and Asd (aspartate semialdehyde dehydrogenase, required for cell wall synthesis) creates significantly attenuated strains .

• Antigen delivery mechanisms: The type III secretion system (T3SS) of attenuated Y. pseudotuberculosis can be exploited to deliver protective antigens directly to the host immune system .

Case Study: Y. pseudotuberculosis PB1+ strain (χ10069)
A novel recombinant attenuated Y. pseudotuberculosis PB1+ strain (χ10069) engineered with ΔyopK ΔyopJ Δasd triple mutations has been used to deliver Y. pestis fusion protein YopENt138-LcrV as a protective antigen :

The χ10069(pYA5199) strain:

• Constitutively synthesized and secreted the YopENt138-LcrV fusion protein via T3SS at 37°C under calcium-deprived conditions

• Rapidly colonized Peyer's patches after oral administration

• Induced significant protective immunity against subcutaneous and intranasal challenges with virulent Y. pestis

• Also provided protection against Y. enterocolitica and Y. pseudotuberculosis challenges

Future Directions:
The maeA enzyme itself could potentially be incorporated into vaccine strategies:

• As a metabolic target for further attenuation of vaccine strains

• As a potential antigen if surface-exposed or secreted variants exist

• As a metabolic regulator to improve vaccine strain performance

This research area demonstrates how understanding both the pathogenicity mechanisms and metabolic functions of Y. pseudotuberculosis can contribute to vaccine development strategies.

What inhibitors of NAD-dependent malic enzymes have been identified, and how might they interact with Y. pseudotuberculosis maeA?

Several inhibitors of malic enzymes have been identified, providing insights into potential inhibitory mechanisms for Y. pseudotuberculosis maeA:

Known Inhibitor Classes:

• Fumarate Analogs: Studies on human mitochondrial NAD(P)+-dependent malic enzyme have identified several inhibitors :

  • Oxaloacetate

  • Diethyl oxalacetate (IC₅₀ ≈ 2.5 mM)

  • Dimethyl fumarate

• Natural Product Derivatives: Research on human NAD(P)+-dependent malic enzyme 2 (ME2) identified:

  • NPD387 and its derivative NPD389 (IC₅₀ ≈ 4.63 ± 0.36 μM without detergent; 5.59 ± 0.38 μM with 0.01% Brij-35)

Mechanisms of Inhibition:
Different inhibitors exhibit distinct mechanisms:

Screening Approaches:
To identify inhibitors for Y. pseudotuberculosis maeA:

• High-throughput screening (HTS):

  • Establish a robust assay system with an appropriate Z′ factor (>0.5) and S/N ratio

  • Include detergents (e.g., 0.01% Brij-35) to exclude false positives

  • Screen diverse compound libraries (natural products often yield hits)

• Structure-based design:

  • If structural data is available, conduct in silico screening

  • Focus on compounds targeting the active site or allosteric regulatory sites

• Thermal shift assays:

  • Verify direct binding of potential inhibitors

  • Distinguish between specific binding and non-specific effects

Potential Applications:
Specific inhibitors of Y. pseudotuberculosis maeA could:

• Serve as research tools to understand metabolic requirements during infection

• Provide starting points for the development of novel antibacterial agents

• Enable metabolic engineering approaches for attenuated vaccine strains

The identification of selective inhibitors requires detailed understanding of structural and mechanistic differences between bacterial and human malic enzymes.

What structural and functional similarities exist between Y. pseudotuberculosis maeA and other bacterial malic enzymes?

Comparative analysis of malic enzymes across species reveals important structural and functional relationships:

• Human mitochondrial NAD(P)+-dependent malic enzyme contains four domains (A-D)

• Domains B and C, along with residues from domain A, form the active site

• The NAD+ cofactor binds in a cleft between domains A and C

• Bacterial malic enzymes are predicted to share this general organization but may have species-specific variations

Catalytic Mechanism:
The reaction proceeds through several steps:

• Binding of divalent metal ion (usually Mn²⁺ or Mg²⁺)

• Sequential binding of NAD+ and L-malate

• Oxidation of malate to oxaloacetate with reduction of NAD+ to NADH

• Decarboxylation of oxaloacetate to form pyruvate and CO₂

• Product release

Conservation of Key Residues:
Functional residues are typically highly conserved across species:

Conformational Changes:
Malic enzymes undergo significant conformational changes during catalysis:

• Open form: substrate accessible

• Closed form: catalytically active

• Allosteric inhibitors may impede the conformational change from open to closed form

Oligomeric State:

• Human m-NAD(P)-ME functions as a tetramer

• Bacterial malic enzymes often exist as dimers or tetramers

• Oligomerization can affect enzyme stability and activity

Comparative structural and functional analysis between Y. pseudotuberculosis maeA and other malic enzymes could reveal species-specific features that might be exploited for selective targeting or metabolic engineering applications.

How do environmental conditions affect Y. pseudotuberculosis maeA expression and activity?

Y. pseudotuberculosis encounters diverse environments during its lifecycle, from external reservoirs to various host niches, all of which can influence maeA expression and activity:

Temperature Regulation:
Y. pseudotuberculosis must adapt to temperatures ranging from environmental (4-25°C) to mammalian host (37°C) conditions:

• Low temperatures (4-25°C): Often associated with environmental persistence and may involve different metabolic requirements

• Host temperature (37°C): Activates virulence factors, including the type III secretion system

• Temperature shifts likely trigger metabolic reprogramming that could involve maeA regulation

Oxygen Availability:
Oxygen tension varies significantly across infection sites:

• Intestinal lumen: Relatively anaerobic

• Intestinal epithelium: Microaerobic

• Deeper tissues (liver, spleen): Varying oxygen tensions

• Adaptation to these conditions may involve differential regulation of central metabolism enzymes including maeA

Nutrient Availability:
Different host niches provide distinct nutrient profiles:

pH Effects:
Y. pseudotuberculosis encounters various pH environments:

• Gastric passage: Extremely acidic (pH 1-2)

• Small intestine: Slightly alkaline (pH 7-8)

• Intracellular environment: Mildly acidic (pH 4.5-6.5)

• The decarboxylation reaction catalyzed by maeA could contribute to pH homeostasis under acidic conditions

Iron Restriction:
Iron limitation is a common host defense mechanism:

• May necessitate metabolic adaptations

• Could potentially influence expression or activity of iron-containing enzymes

• While maeA typically requires Mn²⁺ or Mg²⁺, iron availability might indirectly affect its expression through global metabolic adjustments

Research Approaches:
To investigate environmental regulation of maeA:

• Transcriptomics/proteomics: Compare maeA expression under different environmental conditions

• Reporter systems: Construct maeA promoter-reporter fusions to monitor expression in real-time

• Biochemical characterization: Assess enzyme activity under varying pH, temperature, and ionic conditions

• In vivo expression studies: Monitor maeA expression during infection using animal models

Understanding how environmental conditions regulate maeA expression and activity could provide insights into Y. pseudotuberculosis metabolism during different stages of infection and identify potential intervention points.